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To the Editor: 
A recent report by Colao et al. [1] indicates that a significant proportion of patients harboring 
prolactinomas treated with cabergoline will have persistence of remission of hyperprolactinemia 
following withdrawal of the drug. The prolactin and tumor control rates in the study suggest that 
medical therapy will become increasingly important for the management of all prolactinomas. 
Currently, surgery remains an option only for those patients in whom medical therapy has failed 
or in those with microadenomas. The recent results from Colao et al. [1] demonstrated an 
impressive 70% cure rate following cabergoline treatment of microprolactinomas; these findings 
are likely to further reduce the number of patients seeking surgical treatment [2]. Several factors, 
however, must be considered in the determination to use medical therapy for prolactinomas. In 
addition to control rate, factors such as the patient's medical history, personal preference and the 
cost of treatment should be considered. The authors have undertaken a simple comparative study 
of the relative cost and efficacy of medical or surgical management in those patients with 
microprolactinomas. 
The cost of medical treatment was estimated by determining the cost of medication over 
the expected period of treatment. The University of Utah Hospital pharmacy sells cabergoline 
(Dostinex; Pharmacia & Upjohn Co., Kalamazoo MI) at $953.70 for 30 (0.5 mg) tablets, or 
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from 0.5 to 2 mg/week. Assuming a mean dose of 1 mg per week, the cost per year of treatment 
is $31.79 x 2 x 52 = $3306.16. The median treatment period prior to withdrawal in the study by 
Colao [1] was 48 months with a median dose of 1 mg per week. Thus, the 4-year cost of 
medication alone will reach $13,224.64 and the total cost of treatment must also include several 
outpatient visits in addition to serial pituitary MRI studies (each at an average payment of 
$1025.00 in our market) and serum PRL tests to monitor progress. The total cost of treatment 
will therefore exceed $15,000. Adverse events associated with the use of cabergoline as reported 
by Pharmacia include gastrointestinal upset (nausea, constipation), CNS irregularities (headache, 
dizziness), asthenia, or fatigue symptoms most commonly, and occur in a total of 21 % of 
patients. Following normalization of PRL levels and documented disappearance of the 
microadenoma, the medication will be discontinued, and according to the study by Colao et al. 
[1], 70% of patients will have no further recurrence of hyperprolactinemeia, to be monitored by 
serial follow-up PRL levels. 
To assess the cost of surgical resection, records for the last 50 patients admitted to the 
University of Utah Hospital for surgical resection of pituitary adenoma were reviewed to 
determine hospital and surgeon payments by insurance companies (a combination of both private 
and federal payers, representing a spectrum of payer mix expected in most large teaching 
hospitals). Hospital payments included all care delivered in the operative intervention and 
perioperative period (including pre- and postoperative laboratory studies and anesthesia care). 
Surgical care is reimbursed to include 3 months of postoperative care. The total cost of surgical 
care including hospital and surgeon payments averages $9865.19 (Table 1). 
Following surgical resection, a 91 % long-term control rate, with follow-up of at least 5 





University of Utah Institutional Repository 
Author Manuscript Couldwell et al. 3 
pituitary surgeons have obtained similar results [4-7]. Mortality is expected to be zero and 
morbidity minimal (primarily related to cerebrospinal fluid leak in less than 5% of patients, 
transient diabetes insipidus and electrolyte abnormalities in less than a total of 10% of otherwise 
healthy individuals) with contemporary surgical treatment of microadenomas by experienced 
surgeons [8]. The efficacy of surgery can be determined with great accuracy with a single 
fasting AM PRL level drawn on the first postoperative day (determination of long-term control is 
immediate) [3], and normalization of PRL levels eliminates the need to obtain follow-up imaging 
studies after surgery. Serum PRL levels are followed every 6 months hence. Taken together, the 
surgical option remains a viable and cost-effective alternative to medical therapy in this subset of 
patients, especially in those patients with microadenomas associated with prolactin levels less 
than 200 ng/ml, in whom surgical cure would be anticipated [9]. 
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Table 1. Cost of surgical care for patients treated with surgical resection for diagnosed pituitary 
adenoma. 
Range Mean 
Hospital Payments: $3050.83-14.151.05 $8392.47 
Surgeon Payments: $619.09-5035.00 $1472.72 
Total: $9865.19 
